Literature DB >> 9689032

Antiangiogenic gene therapy.

J Folkman1.   

Abstract

Mesh：

Year:  1998        PMID： 9689032      PMCID： PMC33874          DOI： 10.1073/pnas.95.16.9064

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  29 in total

1.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth.

Authors:  P Lin; P Polverini; M Dewhirst; S Shan; P S Rao; K Peters
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

Authors:  P C Maisonpierre; C Suri; P F Jones; S Bartunkova; S J Wiegand; C Radziejewski; D Compton; J McClain; T H Aldrich; N Papadopoulos; T J Daly; S Davis; T N Sato; G D Yancopoulos
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

3.  Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470.

Authors:  N Klauber; R M Rohan; E Flynn; R J D'Amato
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

4.  Why are we doing so much cancer gene therapy? Disentangling the scientific basis from the origins of gene therapy.

Authors:  P R Lowenstein
Journal:  Gene Ther       Date:  1997-08       Impact factor: 5.250

5.  Gene therapy for cancer.

Authors:  R M Blaese
Journal:  Sci Am       Date:  1997-06       Impact factor: 2.142

6.  Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity.

Authors:  M Xu; D Kumar; S Srinivas; L J Detolla; S F Yu; S A Stass; A J Mixson
Journal:  Hum Gene Ther       Date:  1997-01-20       Impact factor: 5.695

7.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

8.  Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.

Authors:  C Suri; P F Jones; S Patan; S Bartunkova; P C Maisonpierre; S Davis; T N Sato; G D Yancopoulos
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

Review 9.  Gene therapy for cancer: what have we done and where are we going?

Authors:  J A Roth; R J Cristiano
Journal:  J Natl Cancer Inst       Date:  1997-01-01       Impact factor: 13.506

10.  Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.

Authors:  T Tanaka; Y Manome; P Wen; D W Kufe; H A Fine
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440
View more
  28 in total

Review 1.  [Progress in molecular medicine: "laser capture microdissection"].

Authors:  S R Bornstein; H S Willenberg; W A Scherbaum
Journal:  Med Klin (Munich)       Date:  1998-12-15

Review 2.  The role of angiogenesis in rheumatoid arthritis: recent developments.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.

Authors:  R Abramovitch; H Dafni; M Neeman; A Nagler; M Pines
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

4.  Cloning and identification of an angiostatic molecule IP10/crg -2.

Authors:  Zhi-Guo Liu; Jing-Hua Yang; Hua-Zhang An; Hai-Yan Wang; Feng-Tian He; Zhe-Yi Han; Ying Han; Han-Ping Wu; Bing Xiao; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

5.  Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice.

Authors:  A L Feldman; N P Restifo; H R Alexander; D L Bartlett; P Hwu; P Seth; S K Libutti
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

6.  Reduced basal and stimulated leukocyte adherence in tumor endothelium of experimental pancreatic cancer.

Authors:  J Schmidt; E Ryschich; S M Maksan; J Werner; M M Gebhard; C Herfarth; E Klar
Journal:  Int J Pancreatol       Date:  1999-12

7.  Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule.

Authors:  J F Rippmann; K Pfizenmaier; R Mattes; W J Rettig; D Moosmayer
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

8.  Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Meena Gujrati; Ian McCutcheon; Dzung H Dinh; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-07       Impact factor: 5.650

Review 9.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

10.  Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model.

Authors:  Roland Kurdow; Arnd S Boehle; Maren Ruhnke; Renata Mendoza; Lars Boenicke; Bence Sipos; Bodo Schniewind; Peter Dohrmann; Holger Kalthoff
Journal:  Langenbecks Arch Surg       Date:  2003-07-25       Impact factor: 3.445
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.